Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases

Journal of Immunology

Volumn 180, Issue 9, 2008, Pages 6070-6076

  Liu, Xuebin ^a   Yun, Sang Lee ^a   Yu, Cheng Rong ^a   Egwuagu, Charles E ^a,b  

^a NATIONAL EYE INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; RETINOID BINDING PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; VERY LATE ACTIVATION ANTIGEN 4; CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL DIFFERENTIATION; CELL INFILTRATION; CONTROLLED STUDY; GENE DELETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; RETINA FOLD; TH1 CELL; TH17 CELL; TH2 CELL; UVEORETINITIS; WILD TYPE; ALLERGIC ENCEPHALOMYELITIS; ANIMAL; BRAIN; CELL MOTION; EYE; GENETICS; IMMUNOLOGY; MOUSE MUTANT; MULTIPLE SCLEROSIS; PATHOLOGY; UVEITIS;

ADOPTIVE TRANSFER; ANIMALS; BRAIN; CELL DIFFERENTIATION; CELL MOVEMENT; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EYE; FORKHEAD TRANSCRIPTION FACTORS; INTEGRIN ALPHA4BETA1; MICE; MICE, KNOCKOUT; MULTIPLE SCLEROSIS; STAT3 TRANSCRIPTION FACTOR; TH1 CELLS; UVEITIS;

EID: 44449136105     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.9.6070     Document Type: Article

References (27)

1. Nussenblatt, R. B. 1991. Proctor lecture: experimental autoimmune uveitis: mechanisms of disease and clinical therapeutic indications. Invest. Ophthalmol. Visual Sci. 32: 3131-3141.
2. Tarrant, T. K., P. B. Silver, C. C. Chan, B. Wiggert, and R. R. Caspi. 1998. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis. J. Immunol. 161: 122-127. (Pubitemid 28285514)
3. Tarrant, T. K., P. B. Silver, J. L. Wahlsten, L. V. Rizzo, C. C. Chan, B. Wiggert, and R. R. Caspi. 1999. Interleukin 12 protects from a T helper type 1-mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon γ, nitric oxide, and apoptosis. J. Exp. Med. 189: 219-230. (Pubitemid 29063244)
4. Caspi, R. R., P. B. Silver, C. C. Chan, B. Sun, R. K. Agarwal, J. Wells, S. Oddo, Y. Fujino, F. Najafian, and R. L. Wilder. 1996. Genetic susceptibility to experimental autoimmune uveoretinitis in the rat is associated with an elevated Th1 response. J. Immunol. 157: 2668-2675. (Pubitemid 126450484)
5. Amadi-Obi, A., C. R. Yu, X. Liu, R. M. Mahdi, G. L. Clarke, R. B. Nussenblatt, I. Gery, Y. S. Lee, and C. E. Egwuagu. 2007. T(H)17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat. Med. 13: 711-718. (Pubitemid 46889754)
6. Dullforce, P. A., G. W. Seitz, K. L. Garman, J. A. Michael, S. M. Crespo, R. J. Fleischman, S. R. Planck, D. C. Parker, and J. T. Rosenbaum. 2006. Antigen- specific accumulation of naive, memory, and effector CD4 T cells during anterior uveitis monitored by intravital microscopy. Cell. Immunol. 239: 49-60. (Pubitemid 43927658)
7. Crane, I. J., and J. V. Forrester. 2005. Th1 and Th2 lymphocytes in autoimmune disease. Crit. Rev. Immunol. 25: 75-102. (Pubitemid 40910583)
8. Nussenblatt, R. B. 2002. Bench to bedside: new approaches to the immunotherapy of uveitic disease. Int. Rev. Immunol. 21: 273-289.
9. Mathur, A. N., H. C. Chang, D. G. Zisoulis, G. L. Stritesky, Q. Yu, J. T. O'Malley, R. Kapur, D. E. Levy, G. S. Kansas, and M. H. Kaplan. 2007. Stat3 and Stat4 direct development of IL-17-secreting Th cells. J. Immunol. 178: 4901-4907. (Pubitemid 46595272)
10. Yang, X. O., A. D. Panopoulos, R. Nurieva, S. H. Chang, D. Wang, S. S. Watowich, and C. Dong. 2007. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J. Biol. Chem. 282: 9358-9363.
11. Calder, V. L., and S. L. Lightman. 1992. Experimental autoimmune uveoretinitis (EAU) versus experimental allergic encephalomyelitis (EAE): a comparison of T cell-mediated mechanisms. Clin. Exp. Immunol. 89: 165-169.
12. Takase, H., C. R. Yu, X. Liu, C. Fujimoto, I. Gery, and C. E. Egwuagu. 2005. Induction of suppressors of cytokine signaling (SOCS) in the retina during experimental autoimmune uveitis (EAU): potential neuroprotective role of SOCS proteins. J. Neuroimmunol. 168: 118-127. (Pubitemid 41396409)
13. Egwuagu, C. E., C. R. Yu, M. Zhang, R. M. Mahdi, S. J. Kim, and I. Gery. 2002. Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: implications for Th cell lineage commitment and maintenance. J. Immunol. 168: 3181-3187. (Pubitemid 34250377)
14. Yu, C. R., R. M. Mahdi, S. Ebong, B. P. Vistica, J. Chen, Y. Guo, I. Gery, and C. E. Egwuagu. 2004. Cell proliferation and STAT6 pathways are negatively regulated in T cells by STAT1 and suppressors of cytokine signaling. J. Immunol. 173: 737-746. (Pubitemid 38924247)
15. Nurieva, R., X. O. Yang, G. Martinez, Y. Zhang, A. D. Panopoulos, L. Ma, K. Schluns, Q. Tian, S. S. Watowich, A. M. Jetten, and C. Dong. 2007. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448: 480-483. (Pubitemid 47123514)
16. Korn, T., E. Bettelli, W. Gao, A. Awasthi, A. Jager, T. B. Strom, M. Oukka, and V. K. Kuchroo. 2007. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448: 484-487. (Pubitemid 47123515)
17. Kroenke, M. A., and B. M. Segal. 2007. Th17 and Th1 responses directed against the immunizing epitope, as opposed to secondary epitopes, dominate the autoimmune repertoire during relapses of experimental autoimmune encephalomyelitis. J. Neurosci. Res. 85: 1685-1693. (Pubitemid 46849616)
18. Martin, A. P., L. V. de Moraes, C. E. Tadokoro, A. G. Commodaro, E. Urrets-Zavalia, G. A. Rabinovich, J. Urrets-Zavalia, L. V. Rizzo, and H. M. Serra. 2005. Administration of a peptide inhibitor of α4-integrin inhibits the development of experimental autoimmune uveitis. Invest. Ophthalmol. Visual Sci. 46: 2056-2063.
19. Greenwood, J., Y. Wang, and V. L. Calder. 1995. Lymphocyte adhesion and transendothelial migration in the central nervous system: the role of LFA-1, ICAM-1, VLA-4, and VCAM-1. Immunology 86: 408-415.
20. El Kasmi, K. C., J. Holst, M. Coffre, L. Mielke, A. de Pauw, N. Lhocine, A. M. Smith, R. Rutschman, D. Kaushal, Y. Shen, et al. 2006. General nature of the STAT3-activated anti-inflammatory response. J. Immunol. 177: 7880-7888.
21. Murray, P. J. 2006. STAT3-mediated anti-inflammatory signalling. Biochem. Soc. Trans. 34: 1028-1031. (Pubitemid 46768982)
22. Xu, H., A. Manivannan, J. Liversidge, P. F. Sharp, J. V. Forrester, and I. J. Crane. 2003. Requirements for passage of T lymphocytes across non-inflamed retinal microvessels. J. Neuroimmunol. 142: 47-57. (Pubitemid 38368587)
23. Wooten, D. K., X. Xie, D. Bartos, R. A. Busche, G. D. Longmore, and S. S. Watowich. 2000. Cytokine signaling through Stat3 activates integrins, promotes adhesion, and induces growth arrest in the myeloid cell line 32D. J. Biol. Chem. 275: 26566-26575.
24. + T cell line and clone that induce experimental autoimmune uveoretinitis in B10.A mice. J. Immunol. 156: 1654-1660.
25. Harris, T. J., J. F. Grosso, H. R. Yen, H. Xin, M. Kortylewski, E. Albesiano, E. L. Hipkiss, D. Getnet, M. V. Goldberg, C. H. Maris, et al. 2007. Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17- dependent autoimmunity. J. Immunol. 179: 4313-4317.
26. Acosta-Rodriguez, E. V., L. Rivino, J. Geginat, D. Jarrossay, M. Gattorno, A. Lanzavecchia, F. Sallusto, and G. Napolitani. 2007. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8: 639-646. (Pubitemid 46785128)
27. Luger, D., P. B. Silver, J. Tang, D. Cua, Z. Chen, Y. Iwakura, E. P. Bowman, N. M. Sgambellone, C.-C. Chan, and R. R. Caspi. 2008. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J. of Exp. Med. In press.